Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist

The go-to CMC and biomanufacturing podcast for bioprocess development scientists and CMC leaders scaling biologics into regulatory-ready therapies with less trial and error. Practical, execution-focused, and strategic guidance on CMC development, tech transfer, scale-up, GMP readiness, CDMO partnerships, and manufacturing economics for biologics, cell and gene therapies, cultivated meat, and biomaterials. Hosted by Dr. David Brühlmann, CMC strategist, former Bioprocess Innovation Manager at Merck, PhD in glycoengineering, and close to 20 years of biomanufacturing experience. Smart Biotech Scientist delivers actionable insights for the people doing the hard work of turning promising molecules into scalable, regulatory-ready therapies. This podcast is for you if: You are a process development scientist or CMC lead managing a technology transfer, scale-up, or CDMO partnership You are a biologics developer working on upstream or downstream process development, cell culture optimization, or GMP manufacturing readiness You are a biotech founder preparing for an IND filing or Series A fundraise, and need a CMC strategy that holds up under investor and regulatory scrutiny You are building or advising an early-stage biopharma team and need to make smart manufacturing decisions with limited resources What you will learn: CMC strategy and regulatory planning, bioprocess scale-up from lab to clinical and commercial manufacturing, cell culture process development and media optimization, technology transfer best practices, CDMO selection and partnership management, hybrid modeling, manufacturing economics, continuous manufacturing, digitization, and Industry 4.0 in biopharma. Top 10 life sciences podcast with 200+ episodes and guests from Merck, FUJIFILM Irvine Scientific, Cytiva, KBI Biopharma, Eppendorf, and biotech innovators worldwide. New episodes released weekly. Subscribe and join 400+ biotech leaders already using these insights to accelerate development, reduce manufacturing costs, and de-risk scale-up. Next Steps: Get the 5-day CMC email course: https://smartbiotechscientist.com/#cmc Visit the website: https://smartbiotechscientist.com Email us: hello@bruehlmann-consulting.com

  1. 1d ago

    305: Over 90% Antibody Galactosylation Through Cell Line Engineering Alone: Built In Before Scale-Up with Ioscani Jiménez del Val and Gertjan Bartlema - Part 1

    Glycosylation, as a critical quality attribute, remains one of the most challenging variables to control in the production and optimization of therapeutic proteins. Even minor fluctuations in glycan profiles can make or break a promising antibody, impacting quality, efficacy, and commercial viability. Ioscani Jiménez del Val, Associate Professor at University College Dublin and scientific co-founder of Glyvantis Bio, has joined forces with biotech leader Gertjan Bartlema to launch the company and introduce Galixa™, a glycoengineering platform designed to give developers greater control over antibody galactosylation. Topics discussed: Personal journeys into biotech and what sparked long-term passion for the field (04:04)The team dynamic and motivation to bring promising scientific advancements out of academia and into real-world application (05:32)Why glycosylation is a critical quality attribute and so difficult to control in therapeutic proteins (07:41)The commercial perspective on current industry solutions versus a proactive, root-cause approach to glycosylation control (09:49)How the Galixa technology works, including details on cell line engineering and addressing metabolic and cellular bottlenecks (13:14)The role of computational modeling (ChompAct) in identifying and validating engineering targets (15:45)The importance of reliable and robust data as a catalyst for industry adoption and next steps in scaling up new bioprocessing technologies (17:39)Application of the technology to more complex biologics such as bispecifics and those with highly branched glycans, as well as potential limitations (18:36)Smart insight: Most biomanufacturers patch glycosylation variability late in development, often with media tweaks. Glyvantis Bio’s approach starts earlier, at cell line development. It engineers CHO cells to deliver robust, highly consistent N-glycan galactosylation, opening the door to tighter specifications and better antibodies. If this conversation got you thinking about your own glycosylation strategy, here are a few episodes to listen to next: Episodes 227 - 228: Media-Based Glycan Engineering for BiosimilarsEpisodes 43 - 44: Mastering the Art and Science of Glycan Engineering in Drug Development with Henning von HorstenEpisodes 69 - 70: Glycoanalytics Explained: Analysing and Designing Better Biopharmaceutical Drugs with Róisín O’FlahertyEpisodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del ValConnect with Ioscani Jiménez del Val and Gertjan Bartlema Website: www.glyvantisbio.com LinkedIn Ioscani Jiménez del Val: www.linkedin.com/in/ioscanij LinkedIn Gertjan Bartlema: www.linkedin.com/in/gertjan-bartlema Support the show

  2. 6d ago

    304: From Freezer to Bedside: Controlling Cryopreservation Variability in Cell Therapy Manufacturing with Sean Werner - Part 2

    Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances? Biopreservation and cell processing are critical pain points in scaling advanced therapies for global distribution, with variables like cryoprotectant toxicity, transport stability, and automation dictating both cost and clinical success. Sean Werner, CTO of Cell Processing at BioLife Solutions and former Sexton Biotechnologies leader, has seen the real cost when assumptions break down at scale. From container fractures to uncertain analytics, he’s guided teams through the frontline challenges of CMC and biologics. Topics discussed: Why decentralized manufacturing and local storage might be the most practical path forward for delivering cell therapies globally (03:05)Key distribution chain challenges—how logistics complexity escalates with cross-border shipments and the risks of primary packaging failure (03:44)Regulatory expectations for transport validation and the importance of container integrity during shipping (04:49)The growing role of automation and closed systems in reducing manual steps, with a look at current capabilities and future directions (06:41)How more advanced analytics could unlock greater efficiencies and reduce manufacturing costs in cell therapy (07:49)Practical guidance for scientists looking to optimize freezing and thawing processes, including common assumptions to avoid (08:39)When it makes sense to use DMSO, risk management considerations, and whether DMSO-free really means safer (10:39)Long-term aspirations for room-temperature biopreservation and challenging industry assumptions about stability (13:13)The importance of process control and attention to detail in minimizing variability and improving clinical outcomes (14:44)Smart insight: Sean Werner challenged the field to move beyond the cryo status quo: can we develop technologies for stable room temperature storage of living cells and biologics? While the hurdles are immense, questioning established dogma is the only route to transformative change. Above all, he warned, never treat biopreservation as an afterthought—the variability it introduces can undermine even the most promising therapies . As cell therapy matures, early and continual investment in process innovation and discipline will remain key. If this episode has you rethinking freeze-thaw, here’s where to go next. Start with the science behind cryopreservation, then compare two takes on cryoprotectants: DMSO-free formulations and antifreeze-inspired chemistry. Episodes 241 - 242: DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity with Steve OhEpisodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO’s Toxic Side Effects with Jeffrey AllenEpisodes 65 - 66: Freezing and Thawing Cells: the Science Behind Cryopreservation with Mark DavisonEpisodes 129 - 130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason FosterConnect with Sean Werner:  Website: www.biolifesolutions.com LinkedIn: https://www.linkedin.com/in/sean-werner-54688326/ Support the show

  3. Nov 10

    303: From Freezer to Bedside: Controlling Cryopreservation Variability in Cell Therapy Manufacturing with Sean Werner - Part 1

    The integrity of individual cells is the cornerstone of breakthrough cell and gene therapies—but translating lab discoveries into clinical success demands mastering cryopreservation challenges rarely discussed in depth. Sean Werner, Chief Technology Officer of Cell Processing at BioLife Solutions,a leading provider of bioproduction tools and services to the cell and gene therapy and broader biopharma markets, has dedicated his career to safeguarding cell viability from the lab bench through to clinical application. Topics discussed: Sean Werner's unconventional career progression and early experiences in regenerative medicine (03:22)The critical role of cryopreservation in cell and gene therapy product quality (05:59)Biophysics of freezing: ice nucleation, supercooling, and their impact on cell viability (07:32)Hidden pitfalls in cryopreservation, including ice recrystallization and osmotic stress (07:43)Real-world challenges during clinical handling and thawing of cell therapies (11:18)Why the commonly used -1°C per minute freeze rate is not universally optimal (13:09)Difficulties in tracing clinical problems back to early cryopreservation choices (13:54)Importance of evaluating long-term cell function, not just post-thaw viability (15:08)Regulatory expectations around freeze-thaw processes in therapy manufacturing (16:34)Smart insight: Success in cell therapy and advanced biologics is inseparable from mastery of cryopreservation. By adopting an experimental and data-driven mindset—questioning assumptions, customizing protocols, and measuring what truly matters—scientists can better fulfill that original promise: that a single cell, carefully protected, can change the course of medicine for patients worldwide. If this episode has you rethinking freeze-thaw, here’s where to go next. Start with the science behind cryopreservation, then compare two takes on cryoprotectants: DMSO-free formulations and antifreeze-inspired chemistry. Episodes 241 - 242: DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity with Steve OhEpisodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO’s Toxic Side Effects with Jeffrey AllenEpisodes 65 - 66: Freezing and Thawing Cells: the Science Behind Cryopreservation with Mark DavisonEpisodes 129 - 130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason FosterConnect with Sean Werner:  Website: www.biolifesolutions.com LinkedIn: https://www.linkedin.com/in/sean-werner-54688326/ Support the show

  4. Nov 5

    302: Why Rushing Cell Line Development Costs You Months Later: The Analytics-First CMC Strategy with Lars Stöckl and Lena Tholen - Part 2

    Biologics development is full of hidden pitfalls, from selecting the right cell line to navigating analytical assessments that can make or break a therapy's success. Today, we feature Lars Stöckl and Lena Tholen, industry experts from FyoniBio GmbH, who have deep experience guiding biotech teams through the maze of CMC development, troubleshooting both common and unusual product quality challenges. Topics discussed: Key factors in selecting host cell lines and the importance of matching the platform to molecule complexity (02:34)The role of broad analytical assays early in cell line and pool development for better decision-making (03:34)Glycosylation, post-translational modifications, and analytical strategies for both standard antibodies and more complex biotherapeutics (05:10)When and how to conduct developability and manufacturability assessments, especially for novel or specialized molecules (06:55)Troubleshooting glycosylation and aggregation problems—when to tweak the process and when to reconsider the molecule (08:05)Importance of clear, direct communication with clients regarding manufacturability and process viability (09:32)Example of how different CHO cell lines can dramatically impact molecule outcome and company trajectory (12:08)Keeping pace with technological advances through collaboration, conferences, and feasibility studies with startups (13:55)The move toward customization over standardization in cell line and process development (18:07)Smart insight: The future of bioprocess development lies in a customized, molecule-centric approach. Rather than relying on generic, pre-set development platforms, success comes from carefully matching cell lines, processes, and analytical methods to the unique requirements of each molecule. True innovation and commercial success arise from adapting everything—cell line, process, analytics—to the molecule at hand. Lars and Lena’s main point is that early choices about the host cell line, the analytics and the partner decide what’s possible later on. The episodes below take that idea further. One looks at the mechanics of cell line development, one at why promising molecules fail to manufacture, and two at outsourcing CMC work from the sponsor’s side. Episodes 117 - 118: Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea GoughEpisodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan SharfsteinEpisodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist’s Guide to CDMO Selection with Sigma MostafaEpisodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark MelvilleConnect with Lars Stöckl and Lena Tholen:  Website: www.fyonibio.com LinkedIn:www.linkedin.com/in/dr-lars-stoeckl LinkedIn: www.linkedin.com/in/lena-tholen-80642a11a Support the show

  5. Nov 3

    301: Why Rushing Cell Line Development Costs You Months Later: The Analytics-First CMC Strategy with Lars Stöckl and Lena Tholen - Part 1

    How can small biotech companies navigate increasing molecular complexity, tight budgets, and the ever-present pressure to accelerate timelines while ensuring long-term process success? In this episode, David Brühlmann welcomes Lena Tholen and Lars Stöckl of FyoniBio GmbH—two scientists who’ve dedicated their careers to optimizing cell line and process development for biopharma clients. Topics covered in this episode: The trend toward outsourcing CMC development and the reasons behind it for both large pharma and small biotechs (07:27)How specialized CDMOs innovate and continuously improve cell line development platforms, giving clients access to new options and efficiencies (10:36)Real-world experience navigating project pitfalls from discovery to clinical studies—including differences between cell lines and processes (13:38)The importance of retaining key activity assays and critical knowledge in-house—and the risks of over-reliance on consultants (15:04)Key factors that help biotech companies thrive when partnering with CDMOs, including internal expertise, flexibility, and milestone planning (17:32)Smart insight: Product quality and success are designed in early through careful choices about cell lines, processes, and analytical strategies. Streamlined outsourcing and platform innovation can turbocharge development, but only when matched with committed, knowledgeable in-house leadership and measured, forward-thinking investment. The next time a CMC decision seems minor or a shortcut tempting, remember the long game—your product quality, speed to clinic, and future cost may all depend on it. Lars and Lena’s main point is that early choices about the host cell line, the analytics and the partner decide what’s possible later on. The episodes below take that idea further. One looks at the mechanics of cell line development, one at why promising molecules fail to manufacture, and two at outsourcing CMC work from the sponsor’s side. Episodes 117 - 118: Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea GoughEpisodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan SharfsteinEpisodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist’s Guide to CDMO Selection with Sigma MostafaEpisodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark MelvilleConnect with Lars Stöckl and Lena Tholen:  Website: www.fyonibio.com LinkedIn:www.linkedin.com/in/dr-lars-stoeckl LinkedIn: www.linkedin.com/in/lena-tholen-80642a11a Support the show

  6. Oct 29

    300: Where Bioprocess Models Deliver and Where They Overpromise: Choosing Between Hybrid, Mechanistic, and Machine Learning with Moritz von Stosch - Part 2

    Is your process model gathering dust while real-world decisions march on without it? Many technically strong digital tools—no matter how powerful—end up sidelined in bioprocess development. Why is that, and what does it actually take for digital modeling to earn its place at the lab bench? In this episode, David Brühlmann sits down with Moritz von Stosch of HINA Bioventures, a scientist-turned-investor who’s navigated both the technology provider and pharma end-user sides. Moritz von Stosch brings firsthand insights from building digital solutions, deploying them in pharma, and evaluating what actually sticks when the clock is ticking and the stakes are high. Topics discussed: The importance of starting with your purpose when selecting a modeling strategy (03:00)Experimental design: when to use factorial versus random space-filling designs, and the inherent biases each can introduce (04:22)The future of agentic workflows, AI, and autonomous labs in bioprocessing, including the importance and challenges of sensor technologies (06:02)Practical hurdles to implementing fully autonomous laboratories, and the non-obvious value humans still bring (09:09)Adapting mindsets for the evolving role of the bioprocess engineer in a more automated, agent-driven workflow (11:48)Advice for biotech professionals on how to assess the real value in new technologies versus hype, and the role of proprietary algorithms and company stability (13:33)How cultural factors, not just technology, shape the adoption of modeling and digital tools in biotech (16:02)Strategies to help the bioprocess community adopt more innovation while ensuring compliance in regulated environments (17:14)Three key takeaways for staying relevant—including generating data for tomorrow’s questions and balancing curiosity, experimentation, and oversight (19:14)Smart insight: Three takeaways from Moritz von Stosch: Generate data for tomorrow’s questions, not just today’s.Be curious—try, adapt, don’t over-plan.Stay relevant: Use digital tools but keep your human edge (creativity, critical thinking).To keep exploring how modeling and prior knowledge can speed up process development, check out these related conversations: Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael SokolovEpisodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist GernaeyEpisodes 277 - 278: Your Bioprocess Data Already Holds 35% More Yield: From End-to-End Models to Digital Twins with Ignasi Bofarull-ManzanoEpisodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya BurkovConnect with Moritz von Stosch:  Website: www.hinabioventures.com LinkedIn: www.linkedin.com/in/movosto Support the show

  7. Oct 27

    299: Where Bioprocess Models Deliver and Where They Overpromise: Choosing Between Hybrid, Mechanistic, and Machine Learning with Moritz von Stosch - Part 1

    Are you frustrated with reinventing the wheel every time a new molecule enters bioprocess development? Is there a better way to harness data and modeling to accelerate breakthroughs in biotech? The bioprocessing industry is constantly searching for ways to streamline development, reduce costs, and speed new therapies to market—yet leveraging existing knowledge remains a significant challenge. In this episode, David Brühlmann welcomes Moritz von Stosch, partner at HINA Bioventures and a pioneer in digital bioprocess development. Spanning roles from academic research in hybrid modeling to solution design at DataHow and now biotech investment, Moritz von Stosch’s journey traces how mechanistic, hybrid, and machine learning models have (and haven’t) changed process development over the last two decades. Topics discussed: Moritz von Stosch’s career: from early interest in modeling to investment in digital bioprocess tools (03:36)The reality and limitations of platformization and knowledge reuse in large pharma (07:37)Historical context and effectiveness of QbD (Quality by Design) and PAT (Process Analytical Technology) initiatives (10:24)Where modeling can reliably deliver value today in process and clinical development—and where it still overpromises (12:17)The importance of starting to build models early and collecting data that can be reused and repurposed across the process lifecycle (14:17)Approaches to transferring learning between molecules, cell lines, platforms, and the fundamental limitations of this transfer (16:40)Opportunities and difficulties in transferring process knowledge across scales (from microtiter plates to large bioreactors) (18:31)Smart insight: David Brühlmann and Moritz von Stosch agree that models are only useful when they are built on reliable data and interpreted with expert judgment. Models can help biotech teams make better decisions, but they don’t replace human expertise. The real value comes from looking at the whole process, focusing on the data that matters, and making sure knowledge is shared effectively. This can help teams improve bioprocess development and bring new treatments to patients sooner. To keep exploring how modeling and prior knowledge can speed up process development, check out these related conversations: Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael SokolovEpisodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist GernaeyEpisodes 277 - 278: Your Bioprocess Data Already Holds 35% More Yield: From End-to-End Models to Digital Twins with Ignasi Bofarull-ManzanoEpisodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya BurkovConnect with Moritz von Stosch:  Website: www.hinabioventures.com LinkedIn: www.linkedin.com/in/movosto Support the show

  8. Oct 22

    298: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 2

    The entire public record of antibody affinity data comes to about half a million measurements, and by David Younger's estimate, upwards of 75% of it is AlphaSeq data from his own company's publications. His conclusion is that no single company can close the gap alone. So he is asking pharma and AI labs to pay for an experiment and share every result with the other members. In Part 2 of this two-part conversation, David Brühlmann talks with Younger, founding CEO of A-Alpha Bio, whose AlphaSeq platform uses engineered yeast to measure protein interactions at scale. Part 1 set out the shortfall: about 10,000 antibody-antigen structures in the Protein Data Bank against a need of hundreds of thousands to millions. Here Younger explains how the consortium keeps proprietary targets out of the shared pool, who has joined, and why he believes it differs from federated learning. Topics discussed: Challenges faced by individual companies in generating sufficient data for effective AI models (02:17)How a data consortium enables pre-competitive data sharing while protecting proprietary information (06:13)Profiles of ideal consortium members and examples of current participants from pharma and AI model builders (08:36)The consortium’s current focus on VHH antibodies and plans for expansion to broader datasets and applications by 2030 (10:00)Comparison between the consortium approach and federated learning models in data sharing and collaboration (12:01)The main takeaways about the quantity and quality of data needed for machine learning in protein engineering (14:09)Smart insight: As David Younger envisions it, successful maturation of these consortia could fundamentally shift the field by 2030. Multiple consortia could address different scaffolds, data types, and problem statements, alleviating the bottleneck that has long constrained progress. The hope is that abundant, high-quality data will enable breakthrough therapeutic advancements while revealing new gaps that, in turn, inspire the next wave of innovation. Notably, David Younger sees collaboration—not just data scale—as the true secret weapon. Unlike federated learning, consortia incentivize members to share not just data, but experimental insights and best practices, effectively lifting all boats and accelerating collective progress. Curious how others are tackling the data problem in protein design? These episodes pick up right where David Younger leaves off. Episodes 185 - 186: How Generative AI Accelerates Protein Design for Biotech Discovery with Elise de ReusEpisodes 115 - 116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy AgrestiEpisodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan SharfsteinEpisodes 219 - 220: From 10,000 Structures to 1.8 Billion Interactions: Breaking the Data Bottleneck to Engineer Efficacious Therapeutics with Troy LionbergerConnect with David Younger  Company website: www.aalphabio.com LinkedIn: www.linkedin.com/in/david-a-younger/ Data Atlas website: www.atlas.aalphabio.com Support the show

5
out of 5
10 Ratings

About

The go-to CMC and biomanufacturing podcast for bioprocess development scientists and CMC leaders scaling biologics into regulatory-ready therapies with less trial and error. Practical, execution-focused, and strategic guidance on CMC development, tech transfer, scale-up, GMP readiness, CDMO partnerships, and manufacturing economics for biologics, cell and gene therapies, cultivated meat, and biomaterials. Hosted by Dr. David Brühlmann, CMC strategist, former Bioprocess Innovation Manager at Merck, PhD in glycoengineering, and close to 20 years of biomanufacturing experience. Smart Biotech Scientist delivers actionable insights for the people doing the hard work of turning promising molecules into scalable, regulatory-ready therapies. This podcast is for you if: You are a process development scientist or CMC lead managing a technology transfer, scale-up, or CDMO partnership You are a biologics developer working on upstream or downstream process development, cell culture optimization, or GMP manufacturing readiness You are a biotech founder preparing for an IND filing or Series A fundraise, and need a CMC strategy that holds up under investor and regulatory scrutiny You are building or advising an early-stage biopharma team and need to make smart manufacturing decisions with limited resources What you will learn: CMC strategy and regulatory planning, bioprocess scale-up from lab to clinical and commercial manufacturing, cell culture process development and media optimization, technology transfer best practices, CDMO selection and partnership management, hybrid modeling, manufacturing economics, continuous manufacturing, digitization, and Industry 4.0 in biopharma. Top 10 life sciences podcast with 200+ episodes and guests from Merck, FUJIFILM Irvine Scientific, Cytiva, KBI Biopharma, Eppendorf, and biotech innovators worldwide. New episodes released weekly. Subscribe and join 400+ biotech leaders already using these insights to accelerate development, reduce manufacturing costs, and de-risk scale-up. Next Steps: Get the 5-day CMC email course: https://smartbiotechscientist.com/#cmc Visit the website: https://smartbiotechscientist.com Email us: hello@bruehlmann-consulting.com

You Might Also Like